Search

Your search keyword '"Jarolim, Petr"' showing total 567 results
Start Over Author "Jarolim, Petr" Publication Type Academic Journals
567 results on '"Jarolim, Petr"'

1. Using regional sero-epidemiology SARS-CoV-2 anti-S antibodies in the Dominican Republic to inform targeted public health response

Author

Martin, Beatris Mario, Restrepo, Angela Cadavid, Mayfield, Helen J, Paulino, Cecilia Then, De St Aubin, Micheal, Duke, William, Jarolim, Petr, Gutierrez, Emily Zielinski, Ramm, Ronald Skewes, Dumas, Devan, Garnier, Salome, Etienne, Marie Caroline, Pena, Farah, Abdalla, Gabriela, Lopez, Beatriz, de la Cruz, Lucia, Henriquez, Bernarda, Baldwin, Margaret, Sartorius, Benn, Kucharski, Adam, Nilles, Eric James, and Lau, Colleen L

Published
2023

3. Convergence of SARS-CoV-2 spike antibody levels to a population immune setpoint

Author

Nilles, Eric J., Roberts, Kathryn, de St Aubin, Michael, Mayfield, Helen, Restrepo, Angela Cadavid, Garnier, Salome, Abdalla, Gabriela, Etienne, Marie Caroline, Duke, William, Dumas, Devan, Jarolim, Petr, Oasan, Timothy, Peña, Farah, Lopez, Beatriz, Cruz, Lucia de la, Sanchez, Isaac Miguel, Murray, Kristy, Baldwin, Margaret, Skewes-Ramm, Ronald, Paulino, Cecilia Then, Lau, Colleen L., and Kucharski, Adam

Published
2024
Full Text
View/download PDF

5. Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022

Author

Nilles, Eric J., de St. Aubin, Michael, Dumas, Devan, Duke, William, Etienne, Marie Caroline, Abdalla, Gabriela, Jarolim, Petr, Oasan, Timothy, Garnier, Salome, Iihoshi, Naomi, Lopez, Beatriz, de la Cruz, Lucia, Puello, Yosanly Cornelio, Baldwin, Margaret, Roberts, Kathryn W., Pena, Farah, Durski, Kara, Sanchez, Isaac Miguel, Gunter, Sarah M., Kneubehl, Alexander R., Murray, Kristy O., Lino, Allison, Strobel, Sarah, Baez, Amado Alejandro, Lau, Colleen L., Kucharski, Adam, Gutierrez, Emily Zielinski, Skewes-Ramm, Ronald, Vasquez, Marietta, and Paulino, Cecilia Then

Subjects
Epidemics -- Statistics -- Risk factors -- Dominican Republic, Viral antibodies -- Statistics, Antibodies -- Statistics, Health
Abstract

Given widespread unreported SARS-CoV-2 infections, variable immunologic response based on host immunogenicity, vaccine type, viral strain, timing and sequence of vaccine or viral exposure, and humoral waning, the global SARS-CoV-2 [...]

Published
2023
Full Text
View/download PDF

8. Calibrating from Within: Multipoint Internal Calibration of a Quantitative Mass Spectrometric Assay of Serum Methotrexate

Author

Hoffman, Melissa A, Schmeling, Michael, Dahlin, Jayme L, Bevins, Nicholas J, Cooper, Donald P, Jarolim, Petr, Fitzgerald, Robert L, and Hoofnagle, Andrew N

Subjects
Medical Biochemistry and Metabolomics, Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Good Health and Well Being, Calibration, Carbon Isotopes, Chromatography, High Pressure Liquid, Humans, Immunoassay, Isotope Labeling, Limit of Detection, Methotrexate, Tandem Mass Spectrometry, Medical Biotechnology, General Clinical Medicine, Clinical sciences, Medical biochemistry and metabolomics
Abstract

BACKGROUND:Clinical LC-MS/MS assays traditionally require that samples be run in batches with calibration curves in each batch. This approach is inefficient and presents a barrier to random access analysis. We developed an alternative approach called multipoint internal calibration (MPIC) that eliminated the need for batch-mode analysis. METHODS:The new approach used 4 variants of 13C-labeled methotrexate (0.026-10.3 µM) as an internal calibration curve within each sample. One site carried out a comprehensive validation, which included an evaluation of interferences and matrix effects, lower limit of quantification (LLOQ), and 20-day precision. Three sites evaluated assay precision and linearity. MPIC was also compared with traditional LC-MS/MS and an immunoassay. RESULTS:Recovery of spiked analyte was 93%-102%. The LLOQ was validated to be 0.017 µM. Total variability, determined in a 20-day experiment, was 11.5%CV. In a 5-day variability study performed at each site, total imprecision was 3.4 to 16.8%CV. Linearity was validated throughout the calibrator range (r2 > 0.995, slopes = 0.996-1.01). In comparing 40 samples run in each laboratory, the median interlaboratory imprecision was 6.55%CV. MPIC quantification was comparable to both traditional LC-MS/MS and immunoassay (r2 = 0.96-0.98, slopes = 1.04-1.06). Bland-Altman analysis of all comparisons showed biases rarely exceeding 20% when MTX concentrations were >0.4 µM. CONCLUSION:The MPIC method for serum methotrexate quantification was validated in a multisite proof-of-concept study and represents a big step toward random-access LC-MS/MS analysis, which could change the paradigm of mass spectrometry in the clinical laboratory.

Published
2020

9. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies

Author

Loesche, Michael, Karlson, Elizabeth W., Talabi, Opeyemi, Zhou, Guohai, Boutin, Natalie, Atchley, Rachel, Loevinsohn, Gideon, Chang, Jun Bai Park, Hasdianda, Mohammad A., Okenla, Adetoun, Sampson, Elizabeth, Schram, Haley, Magsipoc, Karen, Goodman, Kirsten, Donahue, Lauren, MacGowan, Maureen, Novack, Lewis A., Jarolim, Petr, Baden, Lindsey R., and Nilles, Eric J.

Subjects
Epidemiologic methods, Immune system -- Testing, Viral proteins -- Measurement -- Physiological aspects, Health
Abstract

Estimating the incidence of infections caused by SARS-CoV-2 that are frequently asymptomatic is challenging when using routine passive surveillance methods. Antibodies can provide a record of previous infection, whether symptomatic [...]

Published
2022
Full Text
View/download PDF

10. SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021

Author

Nilles, Eric J., Paulino, Cecilia Then, de St. Aubin, Michael, Restrepo, Angela Cadavid, Mayfield, Helen, Dumas, Devan, Finch, Emilie, Garnier, Salome, Etienne, Marie Caroline, Iselin, Louisa, Duke, William, Jarolim, Petr, Oasan, Timothy, Yu, Jingyou, Wan, Huahua, Peña, Farah, Iihoshi, Naomi, Abdalla, Gabriela, Lopez, Beatriz, Cruz, Lucia de la, Henríquez, Bernarda, Espinosa-Bode, Andres, Puello, Yosanly Cornelio, Durski, Kara, Baldwin, Margaret, Baez, Amado Alejandro, Merchant, Roland C., Barouch, Dan H., Skewes-Ramm, Ronald, Gutiérrez, Emily Zielinski, Kucharski, Adam, and Lau, Colleen L.

Published
2022
Full Text
View/download PDF

11. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

16. Abstract 10465: Abnormal Post Exercise Skeletal Muscle Microvascular Response and Metabolism Correlate With Patient Reported Outcomes in Patients With Intermittent Claudication From Peripheral Artery Disease

Author

Divakaran, Sanjay, Harms, Hans, Robertson, Matthew, Merugumala, Sai, Park, Mi-Ae, Kijewski, Marie, Martell, Laurel, Morgan, Victoria, Barrett, Leanne, Perillo, Anna, Bibbo, Courtney, Yang, David, Jarolim, Petr, Feinberg, Mark W, Lin, Alexander, Bonaca, Marc P, and DI CARLI, MARCELO

Published
2022
Full Text
View/download PDF

19. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

Author

Mahmod, Masliza, Jacoby, Daniel, White, James, Chiribiri, Amedeo, Helms, Adam, Choudhury, Lubna, Michels, Michelle, Bradlow, William, Salerno, Michael, Heitner, Stephen, Prasad, Sanjay, Mohiddin, Saidi, Swoboda, Peter, Mahrholdt, Heiko, Bucciarelli-Ducci, Chiara, Weinsaft, Jonathan, Kim, Han, McCann, Gerry, van Rossum, Albert, Williamson, Eric, Flett, Andrew, Dawson, Dana, Mongeon, F. Pierre, Olivotto, Iacopo, Crean, Andrew, Owens, Anjali, Anderson, Lisa, Biagini, Elena, Newby, David, Berry, Colin, Kim, Bette, Larose, Eric, Abraham, Theodore, Sherrid, Mark, Nagueh, Sherif, Rimoldi, Ornella, Elstein, Eleanor, Autore, Camillo, Neubauer, Stefan, Kolm, Paul, Ho, Carolyn Y., Kwong, Raymond Y., Desai, Milind Y., Dolman, Sarahfaye F., Appelbaum, Evan, Desvigne-Nickens, Patrice, DiMarco, John P., Friedrich, Matthias G., Geller, Nancy, Harper, Andrew R., Jarolim, Petr, Jerosch-Herold, Michael, Kim, Dong-Yun, Maron, Martin S., Schulz-Menger, Jeanette, Piechnik, Stefan K., Thomson, Kate, Zhang, Cheng, Watkins, Hugh, Weintraub, William S., and Kramer, Christopher M.

Published
2019
Full Text
View/download PDF

20. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells

Author

Sewastianik, Tomasz, Guerrera, Maria Luisa, Adler, Keith, Dennis, Peter S., Wright, Kyle, Shanmugam, Vignesh, Huang, Ying, Tanton, Helen, Jiang, Meng, Kofides, Amanda, Demos, Maria G., Dalgarno, Audrey, Patel, Neil A., Nag, Anwesha, Pinkus, Geraldine S., Yang, Guang, Hunter, Zachary R., Jarolim, Petr, Munshi, Nikhil C., Treon, Steven P., and Carrasco, Ruben D.

Published
2019
Full Text
View/download PDF

22. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Author

Berg, David D., Docherty, Kieran F., Sattar, Naveed, Jarolim, Petr, Welsh, Paul, Jhund, Pardeep S., Anand, Inder S., Chopra, Vijay, de Boer, Rudolf A., Kosiborod, Mikhail N., Nicolau, Jose C., O’Meara, Eileen, Schou, Morten, Hammarstedt, Ann, Langkilde, Anna-Maria, Lindholm, Daniel, Sjöstrand, Mikaela, McMurray, John J.V., Sabatine, Marc S., and Morrow, David A.

Published
2022
Full Text
View/download PDF

24. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

Author

Patel, Siddharth M., Morrow, David A., Bellavia, Andrea, Berg, David D., Bhatt, Deepak L., Jarolim, Petr, Leiter, Lawrence A., McGuire, Darren K., Raz, Itamar, Steg, P. Gabriel, Wilding, John P.H., Sabatine, Marc S., Wiviott, Stephen D., Braunwald, Eugene, Scirica, Benjamin M., and Bohula, Erin A.

Subjects
DAPAGLIFLOZIN, BRAIN natriuretic factor, NATRIURETIC peptides, BODY mass index, HEART failure, HEART metabolism disorders, RISK assessment
Abstract

Aim: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT‐proBNP with respect to heart failure risk remains incompletely defined. Methods and results: Data were pooled across three randomized clinical trials enrolling predominantly patients who were overweight or obese with established cardiometabolic disease: SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61. Hospitalization for heart failure (HHF) was examined across strata of baseline BMI and NT‐proBNP. The effect of dapagliflozin versus placebo was assessed for a treatment interaction across BMI categories in patients with or without an elevated baseline NT‐proBNP (≥125 pg/ml). Among 24 455 patients, the median NT‐proBNP was 96 (interquartile range [IQR]: 43–225) pg/ml and the median BMI was 33 (IQR 29–37) kg/m2, with 68% of patients having a BMI ≥30 kg/m2. There was a significant inverse association between NT‐proBNP and BMI which persisted after adjustment for all clinical variables (p < 0.001). Within any range of NT‐proBNP, those at higher BMI had higher risk of HHF at 2 years (comparing BMI <30 vs. ≥40 kg/m2 for NT‐proBNP ranges of <125, 125–<450 and ≥450 pg/ml: 0.0% vs. 0.6%, 1.3% vs. 4.0%, and 8.1% vs. 13.8%, respectively), which persisted after multivariable adjustment (adjusted hazard ratio [HRadj] 7.47, 95% confidence interval [CI] 3.16–17.66, HRadj 3.22 [95% CI 2.13–4.86], and HRadj 1.87 [95% CI 1.35–2.60], respectively). In DECLARE‐TIMI 58, dapagliflozin versus placebo consistently reduced HHF across BMI categories in those with an elevated NT‐proBNP (p‐trend for HR across BMI = 0.60), with a pattern of greater absolute risk reduction (ARR) at higher BMI (ARR for BMI <30 to ≥40 kg/m2: 2.2% to 4.7%; p‐trend = 0.059). Conclusions: The risk of HHF varies across BMI categories for any given range of circulating NT‐proBNP. These findings showcase the importance of considering BMI when applying NT‐proBNP for heart failure risk stratification, particularly for patients with low‐level elevations in NT‐proBNP (125–<450 pg/ml) where there appears to be a clinically meaningful absolute and relative risk gradient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58

Author

Berg, David, Wiviott, Stephen D, RAZ, Itamar, Kamanu, Frederick, Im, KyungAh, Cahn, Avivit, Mosenzon, ofri, Bhatt, Deepak L, Jarolim, Petr, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Huo, Yong, Lopez-sendon, Jose L, Ardissino, Diego, Gause-nilsson, Ingrid A, Sabatine, Marc S, and Morrow, David A

Published
2020
Full Text
View/download PDF

30. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

Author

Zelniker, Thomas A, Morrow, David A, Mosenzon, ofri, Goodrich, Erica, Jarolim, Petr, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Averkov, Oleg V, Budaj, Andrzej, Parkhomenko, Alexander, Ray, Kausik K, Gause-nilsson, Ingrid A, Langkilde, Anna Maria, Fredriksson, Martin, RAZ, Itamar, Sabatine, Marc S, and Wiviott, Stephen D

Published
2020
Full Text
View/download PDF

33. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response.

Author

Mario Martin, Beatris, Cadavid Restrepo, Angela, Mayfield, Helen J., Then Paulino, Cecilia, De St Aubin, Micheal, Duke, William, Jarolim, Petr, Zielinski Gutiérrez, Emily, Skewes Ramm, Ronald, Dumas, Devan, Garnier, Salome, Etienne, Marie Caroline, Peña, Farah, Abdalla, Gabriela, Lopez, Beatriz, de la Cruz, Lucia, Henríquez, Bernarda, Baldwin, Margaret, Sartorius, Benn, and Kucharski, Adam

Published
2023
Full Text
View/download PDF

42. Targeted Delivery of Immunomodulators to Lymph Nodes

Author

Jamil Azzi, Qian Yin, Mayuko Uehara, Shunsuke Ohori, Li Tang, Kaimin Cai, Takaharu Ichimura, Martina McGrath, Omar Maarouf, Eirini Kefaloyianni, Scott Loughhead, Jarolim Petr, Qidi Sun, Mincheol Kwon, Stefan Tullius, Ulrich H. von Andrian, Jianjun Cheng, and Reza Abdi

Subjects
Biology (General), QH301-705.5
Abstract

Active-targeted delivery to lymph nodes represents a major advance toward more effective treatment of immune-mediated disease. The MECA79 antibody recognizes peripheral node addressin molecules expressed by high endothelial venules of lymph nodes. By mimicking lymphocyte trafficking to the lymph nodes, we have engineered MECA79-coated microparticles containing an immunosuppressive medication, tacrolimus. Following intravenous administration, MECA79-bearing particles showed marked accumulation in the draining lymph nodes of transplanted animals. Using an allograft heart transplant model, we show that targeted lymph node delivery of microparticles containing tacrolimus can prolong heart allograft survival with negligible changes in tacrolimus serum level. Using MECA79 conjugation, we have demonstrated targeted delivery of tacrolimus to the lymph nodes following systemic administration, with the capacity for immune modulation in vivo.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results